Thursday 27 April 2017 10:08 AM
Promisia gets R funding from Callaghan for canine dietary supplement
By Rebecca Howard
April 27 (BusinessDesk) - Promisia Integrative, which makes a dietary supplement for sore joints, will receive funds
from Callaghan Innovation for research and development for a new supplement for canines. Its shares surged 19 percent to
3.8 cents.
According to the company, the grant will reimburse 40 percent of the total cost to undertake a two-year approved
programme of research and development.
Its flagship product is Arthrem, a dietary supplement for joint support for humans. The proprietary extract made from
the medicine herb Artemisia annua was originally tested as a malaria treatment in Papua New Guinea. It is grown for
Promisia on a farm in Tanzania.
Chief scientist Sheena Hunt told BusinessDesk said the R will focus on the new canine product and the aim was to launch it sometime this year. She said the biggest challenge is
that the extract is extremely bitter and "it's quite tricky to get dogs to eat it." She said, however, "it's a huge
market" given that 20 percent of dogs over age one suffer from osteoarthritis and 90 percent over eight do and there is
a lack of good long-term solutions in the market. The funds will be used for clinical trials and the aim is to launch
the product sometime this year, she said.
“Promisia’s point of difference is that the company produces natural therapeutic products that are supported by robust
scientific evidence of safety and efficacy. Receipt of this grant from Callaghan Innovation allows us to enter the next
phase of our extensive R programme," said Hunt.
Callaghan Innovation provided financial support for extensive in vitro studies and the human clinical trial of Arthrem
from 2013-2015.
Separately the company said Arthrem has been listed as a complementary medicine with the Therapeutic Goods
Administration in Australia.
Current rules in New Zealand prevent manufacturers of dietary supplements from making any therapeutic claims, even if
there is clinical evidence of such efficacy, the company said. Regulations, however, are different in Australia.
"Listing as a complementary medicine allows us to make evidence-based claims in our advertising and marketing. This
means that in Australia we can refer to our published clinical trial evidence that Arthrem can reduce pain and stiffness
associated with osteoarthritis," said Hunt.
Earlier this month it said sales for the first quarter ended March 31 have continued the positive trend established in
2016. The quarterly sales of $643,588 were up by 169 percent from the same period in 2016.
(BusinessDesk receives assistance from Callaghan Innovation to cover the commercialisation of innovation)
(BusinessDesk)
ends